Pavel Martasek

List of Publications by Year in Descending Order

241 papers	10,829 citations	52 h-index	97 g-index
265 ext. papers	11,459 ext. citations	5.7 avg, IF	5.57 L-index

#	Paper	IF	Citations
241	Molecular characterization of a novel His333Arg variant of human protoporphyrinogen oxidase IX.. *Biochemical and Biophysical Research Communications*, **2021**, 588, 182-186	3.4	
240	Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design. *Pharmaceutics*, **2021**, 13,	6.4	3
239	Heterologous expression and purification of recombinant human protoporphyrinogen oxidase IX: A comparative study. *PLoS ONE*, **2021**, 16, e0259837	3.7	1
238	Novel Mitochondria-targeted Drugs for Cancer Therapy. *Mini-Reviews in Medicinal Chemistry*, **2021**, 21, 816-832	3.2	4
237	Spectroscopic study of in situ-formed metallocomplexes of proton pump inhibitors in water. *Chemical Biology and Drug Design*, **2021**, 97, 305-314	2.9	2
236	Iron Complexes of Flavonoids-Antioxidant Capacity and Beyond. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	10
235	PPO-Inhibiting Herbicides and Structurally Relevant Schiff Bases: Evaluation of Inhibitory Activities against Human Protoporphyrinogen Oxidase. *Processes*, **2021**, 9, 383	2.9	0
234	Formaldehyde Reacts with Amino Acids and Peptides with a Potential Role in Acute Methanol Intoxication. *Journal of Analytical Toxicology*, **2020**, 44, 880-885	2.9	2
233	Anticancer pentamethinium salt is a potent photosensitizer inducing mitochondrial disintegration and apoptosis upon red light illumination. *Journal of Photochemistry and Photobiology B: Biology*, **2020**, 209, 111939	6.7	2
232	Role of mtDNA disturbances in the pathogenesis of Alzheimer's and Parkinson's disease. *DNA Repair*, **2020**, 91-92, 102871	4.3	9
231	Coumarin Tr□er's base derivatives with cyanine substitution as selective and sensitive fluorescent lysosomal probes. *Bioorganic Chemistry*, **2020**, 94, 103447	5.1	3
230	Changes of BMI, steroid metabolome and psychopathology in patients with anorexia nervosa during hospitalization. *Steroids*, **2020**, 153, 108523	2.8	3
229	Highly selective mitochondrial probes based on fluorinated pentamethinium salts: On two-photon properties and microscopic applications. *Dyes and Pigments*, **2020**, 172, 107802	4.6	2
228	A Cyclic Pentamethinium Salt Induces Cancer Cell Cytotoxicity through Mitochondrial Disintegration and Metabolic Collapse. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	4
227	International Porphyria Molecular Diagnostic Collaborative: an evidence-based database of verified pathogenic and benign variants for the porphyrias. *Genetics in Medicine*, **2019**, 21, 2605-2613	8.1	11
226	Strategy for improved therapeutic efficiency of curcumin in the treatment of gastric cancer. *Biomedicine and Pharmacotherapy*, **2019**, 118, 109278	7.5	22
225	Pigments from Filamentous Ascomycetes for Combination Therapy. *Current Medicinal Chemistry*, **2019**, 26, 3812-3834	4.3	

224	Hydrazones as novel epigenetic modulators: Correlation between TET 1 protein inhibition activity and their iron(II) binding ability. *Bioorganic Chemistry*, **2019**, 88, 102809	5.1	6
223	Benzoisothiazole-1,1-dioxide-based synthetic receptor for zinc ion recognition in aqueous medium and its interaction with nucleic acids. *Supramolecular Chemistry*, **2019**, 31, 19-27	1.8	4
222	Pentamethinium salts as ligands for cancer: Sulfated polysaccharide co-receptors as possible therapeutic target. *Bioorganic Chemistry*, **2019**, 82, 74-85	5.1	3
221	Epigenetic agents in combined anticancer therapy. *Future Medicinal Chemistry*, **2018**, 10, 1113-1130	4.1	13
220	Perimidine-based synthetic receptors for determination of copper(II) in water solution. *Supramolecular Chemistry*, **2018**, 30, 218-226	1.8	7
219	Interplay between the APOE Genotype and Possible Plasma Biomarkers in Alzheimer's Disease. *Current Alzheimer Research*, **2018**, 15, 938-950	3	10
218	Diagnostic exome sequencing in early-onset Parkinson's disease confirms VPS13C as a rare cause of autosomal-recessive Parkinson's disease. *Clinical Genetics*, **2018**, 93, 603-612	4	41
217	Interactions Among Polymorphisms of Susceptibility Loci for Alzheimer's Disease or Depressive Disorder. *Medical Science Monitor*, **2018**, 24, 2599-2619	3.2	13
216	Water soluble chromone Schiff base derivatives as fluorescence receptor for aluminium(III). *Supramolecular Chemistry*, **2017**, 29, 1-7	1.8	21
215	Optical probes and sensors as perspective tools in epigenetics. *Bioorganic and Medicinal Chemistry*, **2017**, 25, 2295-2306	3.4	3
214	Methinium colorimetric sensors for the determination of cholesterol sulfate in an aqueous medium. *Sensors and Actuators B: Chemical*, **2017**, 245, 1032-1038	8.5	3
213	Supramolecular Approach in Photodynamic and Photothermal Therapies **2017**, 421-440		
212	Dimethinium Heteroaromatic Salts as Building Blocks for Dual-Fluorescence Intracellular Probes. *ChemPhotoChem*, **2017**, 1, 442-450	3.3	2
211	Hydrophilic, Potent, and Selective 7-Substituted 2-Aminoquinolines as Improved Human Neuronal Nitric Oxide Synthase Inhibitors. *Journal of Medicinal Chemistry*, **2017**, 60, 7146-7165	8.3	11
210	Molecular Diagnostics of Copper-Transporting Protein Mutations Allows Early Onset Individual Therapy of Menkes Disease. *Folia Biologica*, **2017**, 63, 165-173	0.7	2
209	Aluminium(III) sensing by pyridoxal hydrazone utilising the chelation enhanced fluorescence effect. *Journal of Luminescence*, **2016**, 180, 269-277	3.8	30
208	Specific ligands based on Tröger's base derivatives for the recognition of glycosaminoglycans. *Dyes and Pigments*, **2016**, 134, 212-218	4.6	8
207	Genetic and biochemical study of dual hereditary jaundice: Dubin-Johnson and Gilbert's syndromes. Haplotyping and founder effect of deletion in ABCC2. *European Journal of Human Genetics*, **2016**, 24, 704-9	5.3	7

206	MECP2 mutations in Czech patients with Rett syndrome and Rett-like phenotypes: novel mutations, genotype-phenotype correlations and validation of high-resolution melting analysis for mutation scanning. *Journal of Human Genetics*, **2016**, 61, 617-25	4.3	5
205	Mitochondrial Respiration in the Platelets of Patients with Alzheimer's Disease. *Current Alzheimer Research*, **2016**, 13, 930-41	3	52
204	Eight mutations including 5 novel ones in the COL1A1 gene in Czech patients with osteogenesis imperfecta. *Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia*, **2016**, 160, 442-7	1.7	6
203	Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibition by Optimization of the 2-Aminopyridine-Based Scaffold with a Pyridine Linker. *Journal of Medicinal Chemistry*, **2016**, 59, 4913-25	8.3	13
202	Instability of the Human Cytochrome P450 Reductase A287P Variant Is the Major Contributor to Its Antley-Bixler Syndrome-like Phenotype. *Journal of Biological Chemistry*, **2016**, 291, 20487-502	5.4	16
201	RGS2 expression predicts amyloid-□ sensitivity, MCI and Alzheimer's disease: genome-wide transcriptomic profiling and bioinformatics data mining. *Translational Psychiatry*, **2016**, 6, e909	8.6	19
200	Novel CDKL5 Mutations in Czech Patients with Phenotypes of Atypical Rett Syndrome and Early-Onset Epileptic Encephalopathy. *Folia Biologica*, **2016**, 62, 67-74	0.7	
199	Genetic variations in NADPH-CYP450 oxidoreductase in a Czech Slavic cohort. *Pharmacogenomics*, **2015**, 16, 205-15	2.6	4
198	2-Aminopyridines with a Truncated Side Chain To Improve Human Neuronal Nitric Oxide Synthase Inhibitory Potency and Selectivity. *Journal of Medicinal Chemistry*, **2015**, 58, 5548-60	8.3	17
197	Phenyl Ether- and Aniline-Containing 2-Aminoquinolines as Potent and Selective Inhibitors of Neuronal Nitric Oxide Synthase. *Journal of Medicinal Chemistry*, **2015**, 58, 8694-712	8.3	17
196	Striking antitumor activity of a methinium system with incorporated quinoxaline unit obtained by spontaneous cyclization. *ChemBioChem*, **2015**, 16, 555-8	3.8	5
195	New method for recognition of sterol signalling molecules: methinium salts as receptors for sulphated steroids. *Steroids*, **2015**, 94, 15-20	2.8	5
194	Novel 2,4-disubstituted pyrimidines as potent, selective, and cell-permeable inhibitors of neuronal nitric oxide synthase. *Journal of Medicinal Chemistry*, **2015**, 58, 1067-88	8.3	24
193	Hepatoerythropoietic Porphyria Caused by a Novel Homoallelic Mutation in Uroporphyrinogen Decarboxylase Gene in Egyptian Patients. *Folia Biologica*, **2015**, 61, 219-26	0.7	2
192	A Novel Mutation in the FECH Gene in a Czech Family with Erythropoietic Protoporphyria and a Population Study of IVS3-48C Variant Contributing to the Disease. *Folia Biologica*, **2015**, 61, 227-32	0.7	1
191	An Accessible Chiral Linker to Enhance Potency and Selectivity of Neuronal Nitric Oxide Synthase Inhibitors. *ACS Medicinal Chemistry Letters*, **2014**, 5, 56-60	4.3	12
190	Potent and selective double-headed thiophene-2-carboximidamide inhibitors of neuronal nitric oxide synthase for the treatment of melanoma. *Journal of Medicinal Chemistry*, **2014**, 57, 686-700	8.3	33
189	Holoenzyme structures of endothelial nitric oxide synthase - an allosteric role for calmodulin in pivoting the FMN domain for electron transfer. *Journal of Structural Biology*, **2014**, 188, 46-54	3.4	28

188	Combination of chiral linkers with thiophenecarboximidamide heads to improve the selectivity of inhibitors of neuronal nitric oxide synthase. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 4504-4510	2.9	7
187	Simplified 2-aminoquinoline-based scaffold for potent and selective neuronal nitric oxide synthase inhibition. *Journal of Medicinal Chemistry*, **2014**, 57, 1513-30	8.3	34
186	Nitric oxide synthase inhibitors that interact with both heme propionate and tetrahydrobiopterin show high isoform selectivity. *Journal of Medicinal Chemistry*, **2014**, 57, 4382-96	8.3	15
185	Pentamethinium fluorescent probes: The impact of molecular structure on photophysical properties and subcellular localization. *Dyes and Pigments*, **2014**, 107, 51-59	4.6	11
184	Design, Synthesis, Selective Recognition Properties and Targeted Drug Delivery Application. *Handbook of Porphyrin Science*, **2014**, 1-75	0.3	2
183	Parkin (PARK 2) mutations are rare in Czech patients with early-onset Parkinson's disease. *PLoS ONE*, **2014**, 9, e107585	3.7	11
182	Cyclopropyl- and methyl-containing inhibitors of neuronal nitric oxide synthase. *Bioorganic and Medicinal Chemistry*, **2013**, 21, 1333-43	3.4	14
181	Rational design of chemical ligands for selective mitochondrial targeting. *Bioconjugate Chemistry*, **2013**, 24, 1445-54	6.3	24
180	Structure-guided design of selective inhibitors of neuronal nitric oxide synthase. *Journal of Medicinal Chemistry*, **2013**, 56, 3024-32	8.3	25
179	Mutations in ANTXR1 cause GAPO syndrome. *American Journal of Human Genetics*, **2013**, 92, 792-9	11	60
178	Chiral linkers to improve selectivity of double-headed neuronal nitric oxide synthase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 5674-9	2.9	9
177	In search of potent and selective inhibitors of neuronal nitric oxide synthase with more simple structures. *Bioorganic and Medicinal Chemistry*, **2013**, 21, 5323-31	3.4	7
176	Effects of high tidal volume mechanical ventilation on production of cytokines, iNOS, and MIP-1 proteins in pigs. *Experimental Lung Research*, **2013**, 39, 1-8	2.3	6
175	Prediction of coronary vessel involvement on the basis of atherosclerosis risk factor analysis. *Bratislava Medical Journal*, **2013**, 114, 413-7	1.7	
174	Methylated N(hydroxy-L-arginine analogues as mechanistic probes for the second step of the nitric oxide synthase-catalyzed reaction. *Biochemistry*, **2013**, 52, 3062-73	3.2	11
173	A novel sorbent for chromatographic separations: a silica matrix modified with non-covalently bonded tetrakis(cyclodextrin)-porphyrin conjugates. *Journal of Separation Science*, **2013**, 36, 2072-80	3.4	4
172	Immunomagnetic molecular probe with UHPLC-MS/MS: a promising way for reliable bronchial asthma diagnostics based on quantification of cysteinyl leukotrienes. *Journal of Pharmaceutical and Biomedical Analysis*, **2013**, 81-82, 108-17	3.5	7
171	Stress perception and (GT)n repeat polymorphism in haem oxygenase 1 promoter are both risk factors in development of eating disorders. *Folia Biologica*, **2013**, 59, 233-9	0.7	

170	Intramolecular hydrogen bonding: a potential strategy for more bioavailable inhibitors of neuronal nitric oxide synthase. *Bioorganic and Medicinal Chemistry*, **2012**, 20, 2435-43	3.4	28
169	Combination of two chromophores: synthesis and PDT application of porphyrin-pentamethinium conjugate. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 82-4	2.9	15
168	Virtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibe administration: HEAVEN study. *Circulation Journal*, **2012**, 76, 176-83	2.9	52
167	Selective monocationic inhibitors of neuronal nitric oxide synthase. Binding mode insights from molecular dynamics simulations. *Journal of the American Chemical Society*, **2012**, 134, 11559-72	16.4	20
166	Nitric oxide synthases activation and inhibition by metallacarborane-cluster-based isoform-specific affectors. *Journal of Medicinal Chemistry*, **2012**, 55, 9541-8	8.3	18
165	Supramolecular approach for target transport of photodynamic anticancer agents. *Supramolecular Chemistry*, **2012**, 24, 106-116	1.8	9
164	Decreased serum antioxidant capacity in patients with Wilson disease is associated with neurological symptoms. *Journal of Inherited Metabolic Disease*, **2012**, 35, 541-8	5.4	24
163	Identification of six novel P450 oxidoreductase missense variants in Ashkenazi and Moroccan Jewish populations. *Pharmacogenomics*, **2012**, 13, 543-54	2.6	12
162	Symmetric double-headed aminopyridines, a novel strategy for potent and membrane-permeable inhibitors of neuronal nitric oxide synthase. *Journal of Medicinal Chemistry*, **2011**, 54, 2039-48	8.3	33
161	Mutations of human cytochrome P450 reductase differentially modulate heme oxygenase-1 activity and oligomerization. *Archives of Biochemistry and Biophysics*, **2011**, 513, 42-50	4.1	17
160	NOA1 is an essential GTPase required for mitochondrial protein synthesis. *Molecular Biology of the Cell*, **2011**, 22, 1-11	3.5	44
159	Long-term follow-up of Wilson disease: natural history, treatment, mutations analysis and phenotypic correlation. *Liver International*, **2011**, 31, 83-91	7.9	84
158	Coordination conjugates of therapeutic proteins with drug carriers: a new approach for versatile advanced drug delivery. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 5514-20	2.9	27
157	Structural basis for human NADPH-cytochrome P450 oxidoreductase deficiency. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 13486-91	11.5	89
156	Improved synthesis of chiral pyrrolidine inhibitors and their binding properties to neuronal nitric oxide synthase. *Journal of Medicinal Chemistry*, **2011**, 54, 6399-403	8.3	8
155	Adipocyte heme oxygenase-1 induction attenuates metabolic syndrome in both male and female obese mice. *Hypertension*, **2010**, 56, 1124-30	8.5	96
154	APOE epsilon4: a potential modulation factor in Rett syndrome. *Journal of Child Neurology*, **2010**, 25, 546-50	2.5	1
153	Potent, highly selective, and orally bioavailable gem-difluorinated monocationic inhibitors of neuronal nitric oxide synthase. *Journal of the American Chemical Society*, **2010**, 132, 14229-38	16.4	47

152	Heme-coordinating inhibitors of neuronal nitric oxide synthase. Iron-thioether coordination is stabilized by hydrophobic contacts without increased inhibitor potency. *Journal of the American Chemical Society*, **2010**, 132, 798-806	16.4	18
151	Lichen sclerosus et atrophicus-like skin lesions in a patient carrying a novel hydroxymethylbilane synthase mutation. *Blood Cells, Molecules, and Diseases*, **2010**, 45, 176-9	2.1	
150	Porphyrin-cyclodextrin conjugates as a nanosystem for versatile drug delivery and multimodal cancer therapy. *Journal of Medicinal Chemistry*, **2010**, 53, 128-38	8.3	106
149	Exploration of the active site of neuronal nitric oxide synthase by the design and synthesis of pyrrolidinomethyl 2-aminopyridine derivatives. *Journal of Medicinal Chemistry*, **2010**, 53, 7804-24	8.3	40
148	Selective recognition of a saccharide-type tumor marker with natural and synthetic ligands: a new trend in cancer diagnosis. *Analytical and Bioanalytical Chemistry*, **2010**, 398, 1865-70	4.4	17
147	Structure-based design, synthesis, and biological evaluation of lipophilic-tailed monocationic inhibitors of neuronal nitric oxide synthase. *Bioorganic and Medicinal Chemistry*, **2010**, 18, 6526-37	3.4	15
146	Potent and selective neuronal nitric oxide synthase inhibitors with improved cellular permeability. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 554-7	2.9	25
145	Peripheral but crucial: a hydrophobic pocket (Tyr(706), Leu(337), and Met(336)) for potent and selective inhibition of neuronal nitric oxide synthase. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 6258-61	2.9	17
144	Influence of the lung mechanical ventilation with injurious parameters on 7-ketocholesterol synthesis in Sus Scrofa. *BMB Reports*, **2010**, 43, 257-62	5.5	2
143	Parkin mutations and phenotypic features in Czech patients with early-onset Parkinson's disease. *Neuroendocrinology Letters*, **2010**, 31, 187-92	0.3	5
142	Synthesis and enzymatic evaluation of 2- and 4-aminothiazole-based inhibitors of neuronal nitric oxide synthase. *Beilstein Journal of Organic Chemistry*, **2009**, 5, 28	2.5	11
141	Selective neuronal nitric oxide synthase inhibitors and the prevention of cerebral palsy. *Annals of Neurology*, **2009**, 65, 209-17	9.4	71
140	NO formation by neuronal NO-synthase can be controlled by ultrafast electron injection from a nanotrigger. *ChemBioChem*, **2009**, 10, 690-701	3.8	12
139	N-acetyl cysteine averted liver transplantation in a patient with liver failure caused by erythropoietic protoporphyria. *Liver Transplantation*, **2009**, 15, 352-4	4.5	6
138	Czech bibliometric system fosters mediocre research. *Nature*, **2009**, 460, 1079	50.4	1
137	Acute intermittent porphyria--impact of mutations found in the hydroxymethylbilane synthase gene on biochemical and enzymatic protein properties. *FEBS Journal*, **2009**, 276, 2106-15	5.7	10
136	Analogues of 2-aminopyridine-based selective inhibitors of neuronal nitric oxide synthase with increased bioavailability. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 2371-80	3.4	36
135	Detection of DNA variations in the polymorphic hydroxymethylbilane synthase gene by high-resolution melting analysis. *Analytical Biochemistry*, **2009**, 395, 41-8	3.1	5

134	Discovery of highly potent and selective inhibitors of neuronal nitric oxide synthase by fragment hopping. *Journal of Medicinal Chemistry*, **2009**, 52, 779-97	8.3	78
133	Correlation between biochemical findings, structural and enzymatic abnormalities in mutated HMBS identified in six Israeli families with acute intermittent porphyria. *Blood Cells, Molecules, and Diseases*, **2009**, 42, 167-73	2.1	7
132	Methyl Gallate as the Framework for the Construction of Fluorous Building Blocks. *Synthetic Communications*, **2009**, 40, 247-256	1.7	2
131	Isoform-specific differences in the nitrite reductase activity of nitric oxide synthases under hypoxia. *Biochemical Journal*, **2009**, 418, 673-82	3.8	36
130	Synthesis of unsymmetric cyanine dye via merocyanine and their interaction with DNA. *Collection of Czechoslovak Chemical Communications*, **2009**, 74, 1081-1090		6
129	Glycol porphyrin derivatives as potent photodynamic inducers of apoptosis in tumor cells. *Journal of Medicinal Chemistry*, **2008**, 51, 5964-73	8.3	58
128	P49. Only eNOS among the NOS isoforms is a nitrite reductase under hypoxia. *Nitric Oxide - Biology and Chemistry*, **2008**, 19, 54	5	
127	Characterization of two missense variants in the hydroxymethylbilane synthase gene in the Israeli population, which differ in their associations with acute intermittent porphyria. *Molecular Genetics and Metabolism*, **2008**, 94, 343-6	3.7	8
126	Optical sensing of sulfate by polymethinium salt receptors: colorimetric sensor for heparin. *Chemical Communications*, **2008**, 1901-3	5.8	57
125	Minimal pharmacophoric elements and fragment hopping, an approach directed at molecular diversity and isozyme selectivity. Design of selective neuronal nitric oxide synthase inhibitors. *Journal of the American Chemical Society*, **2008**, 130, 3900-14	16.4	88
124	Synthesis of Highly Functionalized Fluorinated Porphyrins. *Supramolecular Chemistry*, **2008**, 20, 237-242	1.8	15
123	Electrophilic polyfluoroalkylating agents based on sulfonate esters. *Journal of Fluorine Chemistry*, **2008**, 129, 235-247	2.1	12
122	Two photon-induced electron injection from a nanotrigger in native endothelial NO-synthase. *ChemPhysChem*, **2008**, 9, 2325-31	3.2	13
121	Defects in ATP Dependent Canalicular Transporter ABCC2. Mutation Study of ABCC2 Gene in a Large Family with Dubin-Johnson syndrome.. *FASEB Journal*, **2008**, 22, 813.6	0.9	
120	Structure-based design and synthesis of N(omega)-nitro-L-arginine-containing peptidomimetics as selective inhibitors of neuronal nitric oxide synthase. Displacement of the heme structural water. *Journal of Medicinal Chemistry*, **2007**, 50, 2089-99	8.3	28
119	Selective L-nitroargininylaminopyrrolidine and L-nitroargininylaminopiperidine neuronal nitric oxide synthase inhibitors. *Bioorganic and Medicinal Chemistry*, **2007**, 15, 1928-38	3.4	20
118	Hydroxyethylene isosteres of selective neuronal nitric oxide synthase inhibitors. *Bioorganic and Medicinal Chemistry*, **2007**, 15, 6096-108	3.4	6
117	Three-fold polyfluoroalkylated amines and isocyanates based on tris(hydroxymethyl)aminomethane (TRIS). *Journal of Fluorine Chemistry*, **2007**, 128, 179-183	2.1	15

116	Mutation analysis of the MECP2 gene in patients of Slavic origin with Rett syndrome: novel mutations and polymorphisms. *Journal of Human Genetics*, **2007**, 52, 342-348	4.3	22
115	Oxygen metabolism by neuronal nitric-oxide synthase. *Journal of Biological Chemistry*, **2007**, 282, 7921-9	5.4	25
114	Oxygen metabolism by endothelial nitric-oxide synthase. *Journal of Biological Chemistry*, **2007**, 282, 28557-28565	5.4	33
113	Corrigendum to "Mammalian mitochondrial nitric oxide synthase: Characterization of a novel candidate" [FEBS Lett. 580 (2006) 455–462]. *FEBS Letters*, **2007**, 581, 2072-2073	3.8	
112	Endothelial cell superoxide anion radical generation is not dependent on endothelial nitric oxide synthase-serine 1179 phosphorylation and endothelial nitric oxide synthase dimer/monomer distribution. *Free Radical Biology and Medicine*, **2006**, 40, 2056-68	7.8	33
111	The role of a conserved serine residue within hydrogen bonding distance of FAD in redox properties and the modulation of catalysis by Ca2+/calmodulin of constitutive nitric-oxide synthases. *Journal of Biological Chemistry*, **2006**, 281, 34246-57	5.4	12
110	Diminished FAD binding in the Y459H and V492E Antley-Bixler syndrome mutants of human cytochrome P450 reductase. *Journal of Biological Chemistry*, **2006**, 281, 35975-82	5.4	43
109	Polyhydroxylated sapphyrins: multisite non-metallic catalysts for activated phosphodiester hydrolysis. *Journal of the American Chemical Society*, **2006**, 128, 432-7	16.4	17
108	Conformationally restricted dipeptide amides as potent and selective neuronal nitric oxide synthase inhibitors. *Journal of Medicinal Chemistry*, **2006**, 49, 6254-63	8.3	22
107	Mammalian mitochondrial nitric oxide synthase: characterization of a novel candidate. *FEBS Letters*, **2006**, 580, 455-62	3.8	37
106	Endothelial nitric oxide synthase reduces nitrite anions to NO under anoxia. *Biochemical and Biophysical Research Communications*, **2006**, 341, 816-21	3.4	128
105	Dynamics of NO rebinding to the heme domain of NO synthase-like proteins from bacterial pathogens. *Nitric Oxide - Biology and Chemistry*, **2006**, 15, 312-27	5	13
104	Plant nitric oxide synthase: a never-ending story?. *Trends in Plant Science*, **2006**, 11, 524-5; author reply 526-8	13.1	281
103	Design, synthesis, and biological testing of potential heme-coordinating nitric oxide synthase inhibitors. *Bioorganic and Medicinal Chemistry*, **2006**, 14, 3185-98	3.4	17
102	Hydroxyl-terminated peptidomimetic inhibitors of neuronal nitric oxide synthase. *Bioorganic and Medicinal Chemistry*, **2006**, 14, 3681-90	3.4	6
101	Branched polyfluorinated triflate—an easily available polyfluoroalkylating agent. *Journal of Fluorine Chemistry*, **2006**, 127, 386-390	2.1	8
100	Analogies and surprising differences between recombinant nitric oxide synthase-like proteins from Staphylococcus aureus and Bacillus anthracis in their interactions with l-arginine analogs and iron ligands. *Journal of Inorganic Biochemistry*, **2006**, 100, 2024-33	4.2	19
99	Reaction Pathways and Stoichiometry of Nitric Oxide Synthase. *FASEB Journal*, **2006**, 20, A41	0.9	

98	Molecular pathology of copper metabolism: Mutation screening in the ATP7A gene in Czech patients with Menkes disease - identification of two novel mutations. *FASEB Journal*, **2006**, 20, A98	0.9	
97	Conformational changes in Nitric Oxide Synthase Isoforms Under High Hydrostatic Pressure. *FASEB Journal*, **2006**, 20, A905	0.9	
96	Mutation analysis of the MECP2 gene in patients with Rett syndrome. *FASEB Journal*, **2006**, 20, A70	0.9	
95	Chromophoric binaphthyl derivatives. *Organic Letters*, **2005**, 7, 3661-4	6.2	9
94	Reductive activation of Cr(Vi) by nitric oxide synthase. *Chemical Research in Toxicology*, **2005**, 18, 834-43	4	16
93	Calcium/calmodulin-dependent nitric oxide synthase activity in the CNS of Aplysia californica: biochemical characterization and link to cGMP pathways. *Journal of Inorganic Biochemistry*, **2005**, 99, 922-8	4.2	20
92	Superoxide Generation from Nitric Oxide Synthase **2005**, 75-91		6
91	Recruitment of governing elements for electron transfer in the nitric oxide synthase family. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 15833-8	11.5	33
90	Structural basis of hereditary coproporphyria. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 14232-7	11.5	64
89	Thermodynamics of oxidation-reduction reactions in mammalian nitric-oxide synthase isoforms. *Journal of Biological Chemistry*, **2004**, 279, 18759-66	5.4	41
88	Potent and selective conformationally restricted neuronal nitric oxide synthase inhibitors. *Journal of Medicinal Chemistry*, **2004**, 47, 703-10	8.3	29
87	Clinical, biochemical and molecular analyses of six patients with isolated cytochrome c oxidase deficiency due to mutations in the SCO2 gene. *Acta Paediatrica, International Journal of Paediatrics*, **2004**, 93, 1312-7	3.1	10
86	The role of tetrahydrobiopterin in superoxide generation from eNOS: enzymology and physiological implications. *Free Radical Research*, **2003**, 37, 121-7	4	172
85	Aromatic reduced amide bond peptidomimetics as selective inhibitors of neuronal nitric oxide synthase. *Journal of Medicinal Chemistry*, **2003**, 46, 1661-9	8.3	40
84	Role of the interdomain linker probed by kinetics of CO ligation to an endothelial nitric oxide synthase mutant lacking the calmodulin binding peptide (residues 503-517 in bovine). *Biochemistry*, **2003**, 42, 6500-6	3.2	16
83	Competition and binding of arginine, imidazole, and aminoguanidine to endothelial nitric oxide synthase: aminoguanidine is a poor model for substrate, intermediate, and arginine analog inhibitor binding. *Nitric Oxide - Biology and Chemistry*, **2003**, 8, 149-54	5	1
82	Cardiac involvement in Wilson disease. *Journal of Inherited Metabolic Disease*, **2002**, 25, 269-77	5.4	51
81	Anti-inflammatory effects of tetrahydrobiopterin on early rejection in renal allografts: modulation of inducible nitric oxide synthase. *FASEB Journal*, **2002**, 16, 1135-7	0.9	40

80	The ratio between tetrahydrobiopterin and oxidized tetrahydrobiopterin analogues controls superoxide release from endothelial nitric oxide synthase: an EPR spin trapping study. *Biochemical Journal*, **2002**, 362, 733-739	3.8	232
79	The ratio between tetrahydrobiopterin and oxidized tetrahydrobiopterin analogues controls superoxide release from endothelial nitric oxide synthase: an EPR spin trapping study. *Biochemical Journal*, **2002**, 362, 733-9	3.8	150
78	EPR and ENDOR characterization of intermediates in the cryoreduced oxy-nitric oxide synthase heme domain with bound L-arginine or N(G)-hydroxyarginine. *Biochemistry*, **2002**, 41, 10375-81	3.2	112
77	Intrinsic and extrinsic modulation of nitric oxide synthase activity. *Chemical Reviews*, **2002**, 102, 1179-90	68.1	174
76	Reaction of tetrahydrobiopterin with superoxide: EPR-kinetic analysis and characterization of the pteridine radical. *Free Radical Biology and Medicine*, **2001**, 31, 975-85	7.8	93
75	Structural basis for pterin antagonism in nitric-oxide synthase. Development of novel 4-oxo-pteridine antagonists of (6R)-5,6,7,8-tetrahydrobiopterin. *Journal of Biological Chemistry*, **2001**, 276, 49133-41	5.4	24
74	Kinetics of CO and NO ligation with the Cys(331)-->Ala mutant of neuronal nitric-oxide synthase. *Journal of Biological Chemistry*, **2001**, 276, 4733-6	5.4	9
73	Reduced amide bond peptidomimetics. (4S)-N-(4-amino-5-[aminoakyl]aminopentyl)-N'-nitroguanidines, potent and highly selective inhibitors of neuronal nitric oxide synthase. *Journal of Medicinal Chemistry*, **2001**, 44, 2667-70	8.3	65
72	Association of the Glu298Asp polymorphism in the endothelial nitric oxide synthase gene with essential hypertension resistant to conventional therapy. *Biochemical and Biophysical Research Communications*, **2001**, 284, 426-30	3.4	82
71	Titration of low K(d) binding sites: binding of arginine analogs to nitric oxide synthases. *Nitric Oxide - Biology and Chemistry*, **2001**, 5, 442-52	5	7
70	Implications for isoform-selective inhibitor design derived from the binding mode of bulky isothioureas to the heme domain of endothelial nitric-oxide synthase. *Journal of Biological Chemistry*, **2001**, 276, 26486-91	5.4	23
69	Crystal structure of the FAD/NADPH-binding domain of rat neuronal nitric-oxide synthase. Comparisons with NADPH-cytochrome P450 oxidoreductase. *Journal of Biological Chemistry*, **2001**, 276, 37506-13	5.4	100
68	Synthesis and evaluation of dipeptide amides containing N omega-nitroarginine and D-2,4-diaminobutyric acids as inhibitors of neuronal nitric oxide synthase. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2001**, 16, 233-9		6
67	Crystal structure of nitric oxide synthase bound to nitro indazole reveals a novel inactivation mechanism. *Biochemistry*, **2001**, 40, 13448-55	3.2	74
66	Crystallographic studies on endothelial nitric oxide synthase complexed with nitric oxide and mechanism-based inhibitors. *Biochemistry*, **2001**, 40, 5399-406	3.2	74
65	1H-pyrazole-1-carboxamidines: new inhibitors of nitric oxide synthase. *Bioorganic and Medicinal Chemistry Letters*, **2000**, 10, 2771-4	2.9	18
64	Mapping the active site polarity in structures of endothelial nitric oxide synthase heme domain complexed with isothioureas. *Journal of Inorganic Biochemistry*, **2000**, 81, 133-9	4.2	28
63	Folic acid reverts dysfunction of endothelial nitric oxide synthase. *Circulation Research*, **2000**, 86, 1129-34	15.7	238

62	The C termini of constitutive nitric-oxide synthases control electron flow through the flavin and heme domains and affect modulation by calmodulin. *Journal of Biological Chemistry*, **2000**, 275, 29225-32	5.4	94
61	Detection of superoxide anion using an isotopically labeled nitrone spin trap: potential biological applications. *FEBS Letters*, **2000**, 473, 58-62	3.8	131
60	ENDOR Spectroscopic Evidence for the Geometry of Binding ofretro-inverso-NŒNitroarginine-Containing Dipeptide Amides to Neuronal Nitric Oxide Synthase. *Journal of the American Chemical Society*, **2000**, 122, 7869-7875	16.4	13
59	Synthesis and evaluation of peptidomimetics as selective inhibitors and active site probes of nitric oxide synthases. *Journal of Medicinal Chemistry*, **2000**, 43, 2938-45	8.3	32
58	ENDOR Studies of l-Arginine and NG-Hydroxy-l-Arginine Bound to All Three Holo-Nitric Oxide Synthase Isozymes. *Journal of the American Chemical Society*, **2000**, 122, 5405-5406	16.4	22
57	EPR spin trapping of superoxide from nitric oxide synthase. *Analusis - European Journal of Analytical Chemistry*, **2000**, 28, 487-492		6
56	Kinetics of NO ligation with nitric-oxide synthase by flash photolysis and stopped-flow spectrophotometry. *Journal of Biological Chemistry*, **1999**, 274, 13105-10	5.4	48
55	Electron spin resonance spin-trapping detection of superoxide generated by neuronal nitric oxide synthase. *Methods in Enzymology*, **1999**, 301, 169-77	1.7	33
54	Zinc content of Escherichia coli-expressed constitutive isoforms of nitric-oxide synthase. Enzymatic activity and effect of pterin. *Journal of Biological Chemistry*, **1999**, 274, 14537-40	5.4	26
53	Tetrahydrobiopterin-dependent inhibition of superoxide generation from neuronal nitric oxide synthase. *Journal of Biological Chemistry*, **1999**, 274, 26736-42	5.4	151
52	Imidazole-containing amino acids as selective inhibitors of nitric oxide synthases. *Bioorganic and Medicinal Chemistry*, **1999**, 7, 1941-51	3.4	27
51	Conformationally-restricted arginine analogues as alternative substrates and inhibitors of nitric oxide synthases. *Bioorganic and Medicinal Chemistry*, **1999**, 7, 1097-104	3.4	22
50	Systematic analysis of coproporphyrinogen oxidase gene defects in hereditary coproporphyria and mutation update. *Human Mutation*, **1999**, 13, 44-53	4.7	30
49	Effect of redox-active drugs on superoxide generation from nitric oxide synthases: biological and toxicological implications. *Free Radical Research*, **1999**, 31, 607-17	4	21
48	ENDOR spectroscopic evidence for the position and structure of NG-hydroxy-L-arginine bound to holo-neuronal nitric oxide synthase. *Biochemistry*, **1999**, 38, 3704-10	3.2	49
47	N(omega)-Nitroarginine-containing dipeptide amides. Potent and highly selective inhibitors of neuronal nitric oxide synthase. *Journal of Medicinal Chemistry*, **1999**, 42, 3147-53	8.3	72
46	Rapid kinetic studies of electron transfer in the three isoforms of nitric oxide synthase. *Biochemical and Biophysical Research Communications*, **1999**, 265, 184-8	3.4	68
45	Assay of isoforms of Escherichia coli-expressed nitric oxide synthase. *Methods in Enzymology*, **1999**, 301, 70-8	1.7	23

44	Crystal structure of constitutive endothelial nitric oxide synthase: a paradigm for pterin function involving a novel metal center. *Cell*, **1998**, 95, 939-50	56.2	593
43	Location of Guanidino Nitrogen of l-Arginine Substrate Bound to Neuronal Nitric Oxide Synthase (nNOS): Determination by Q-band Pulsed ENDOR Spectroscopy. *Journal of the American Chemical Society*, **1998**, 120, 2983-2984	16.4	30
42	Molecular characterization of homozygous variegate porphyria. *Human Molecular Genetics*, **1998**, 7, 1921-5	5.6	45
41	Molecular Characterization of Homozygous Variegate Porphyria. *Human Molecular Genetics*, **1998**, 7, 1921-1925	5.6	36
40	Hereditary coproporphyria. *Seminars in Liver Disease*, **1998**, 18, 25-32	7.3	58
39	The C331A mutant of neuronal nitric-oxide synthase is defective in arginine binding. *Journal of Biological Chemistry*, **1998**, 273, 34799-805	5.4	54
38	Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. *Proceedings of the National Academy of Sciences of the United States of America*, **1998**, 95, 9220-5	11.5	1229
37	Molecular analysis of porphobilinogen (PBG) deaminase gene mutations in acute intermittent porphyria: first study in patients of Slavic origin. *Scandinavian Journal of Clinical and Laboratory Investigation*, **1997**, 57, 217-24	2	15
36	Kinetics of CO ligation with nitric-oxide synthase by flash photolysis and stopped-flow spectrophotometry. *Journal of Biological Chemistry*, **1997**, 272, 12523-8	5.4	35
35	An autoinhibitory control element defines calcium-regulated isoforms of nitric oxide synthase. *Journal of Biological Chemistry*, **1997**, 272, 29769-77	5.4	200
34	Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the nos caveolin binding domain in vivo. *Journal of Biological Chemistry*, **1997**, 272, 25437-40	5.4	639
33	Substrate binding-induced changes in the EPR spectra of the ferrous nitric oxide complexes of neuronal nitric oxide synthase. *Biochemistry*, **1997**, 36, 10987-92	3.2	56
32	Potent and selective inhibition of neuronal nitric oxide synthase by N omega-propyl-L-arginine. *Journal of Medicinal Chemistry*, **1997**, 40, 3869-70	8.3	174
31	Substrate and substrate analog binding to endothelial nitric oxide synthase: electron paramagnetic resonance as an isoform-specific probe of the binding mode of substrate analogs. *Biochemistry*, **1997**, 36, 11821-7	3.2	14
30	Involvement of the reductase domain of neuronal nitric oxide synthase in superoxide anion production. *Biochemistry*, **1997**, 36, 15277-84	3.2	86
29	Selective inhibition of neuronal nitric oxide synthase by N omega-nitroarginine-and phenylalanine-containing dipeptides and dipeptide esters. *Journal of Medicinal Chemistry*, **1997**, 40, 2813-7	8.3	41
28	Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. *Biochemistry*, **1997**, 36, 11293-7	3.2	288
27	Superoxide anion formation from lucigenin: an electron spin resonance spin-trapping study. *FEBS Letters*, **1997**, 403, 127-30	3.8	155

26	Human coproporphyrinogen oxidase. Biochemical characterization of recombinant normal and R231W mutated enzymes expressed in E. coli as soluble, catalytically active homodimers. *Cellular and Molecular Biology*, **1997**, 43, 47-58	1.1	8
25	Electron paramagnetic resonance spectroscopy of the heme domain of inducible nitric oxide synthase: binding of ligands at the arginine site induces changes in the heme ligation geometry. *Biochemistry*, **1996**, 35, 7626-30	3.2	28
24	Characterization of bovine endothelial nitric oxide synthase expressed in E. coli. *Biochemical and Biophysical Research Communications*, **1996**, 219, 359-65	3.4	152
23	Neuronal nitric oxide synthase, a modular enzyme formed by convergent evolution: structure studies of a cysteine thiolate-liganded heme protein that hydroxylates L-arginine to produce NO. as a cellular signal. *FASEB Journal*, **1996**, 10, 552-8	0.9	193
22	Prokaryotic Expression, Purification, Characterization of Intact Modular Constructs of Neuronal Nitric Oxide Synthase. *Methods in Neurosciences*, **1996**, 31, 140-151		1
21	A molecular defect in coproporphyrinogen oxidase gene causing harderoporphyria, a variant form of hereditary coproporphyria. *Human Molecular Genetics*, **1995**, 4, 275-8	5.6	54
20	Modular structure of neuronal nitric oxide synthase: localization of the arginine binding site and modulation by pterin. *Biochemical and Biophysical Research Communications*, **1995**, 210, 288-94	3.4	55
19	High-level expression of functional rat neuronal nitric oxide synthase in Escherichia coli. *Proceedings of the National Academy of Sciences of the United States of America*, **1995**, 92, 8428-32	11.5	252
18	Molecular cloning, sequencing, and functional expression of a cDNA encoding human coproporphyrinogen oxidase. *Proceedings of the National Academy of Sciences of the United States of America*, **1994**, 91, 3024-8	11.5	44
17	Localization of the human coproporphyrinogen oxidase gene to chromosome band 3q12. *Human Genetics*, **1994**, 94, 557-9	6.3	21
16	Coproporphyrinogen oxidase: gene organization and description of a mutation leading to exon 6 skipping. *Human Molecular Genetics*, **1994**, 3, 1325-30	5.6	53
15	Homozygous hereditary coproporphyria caused by an arginine to tryptophane substitution in coproporphyrinogen oxidase and common intragenic polymorphisms. *Human Molecular Genetics*, **1994**, 3, 477-80	5.6	68
14	Hemin and L-arginine regulation of blood pressure in spontaneous hypertensive rats. *Journal of the American Society of Nephrology: JASN*, **1991**, 2, 1078-84	12.7	61
13	Regulation of heme oxygenase gene expression by cobalt in rat liver and kidney. *FEBS Journal*, **1990** , 192, 577-82		50
12	Sensitivity of human tissue heme oxygenase to a new synthetic metalloporphyrin. *Hepatology*, **1989** , 10, 365-9	11.2	63
11	Changes of myocardial functions in acute hepatic porphyrias. Role of heme arginate administration. *Annals of Medicine*, **1989**, 21, 273-6	1.5	12
10	Porphyrinostatic effect of isonicotinic acid hydrazide on porphyric chick embryo and yeast. *International Journal of Biochemistry & Cell Biology*, **1988**, 20, 1281-3		
9	Properties of human kidney heme oxygenase: inhibition by synthetic heme analogues and metalloporphyrins. *Biochemical and Biophysical Research Communications*, **1988**, 157, 480-7	3.4	25

8	Porphyria Cutanea Tarda Manifestation and Therapy. *Annals of the New York Academy of Sciences*, **1987**, 514, 335-336	6.5	3
7	Induction of Acute Attack in Acute Hepatic Porphyrias Experiences with Diagnosis and Therapy over Thirty Years. *Annals of the New York Academy of Sciences*, **1987**, 514, 342-344	6.5	
6	Solid phase extraction and isocratic separation of urinary porphyrins by HPLC. *Biomedical Chromatography*, **1986**, 1, 159-62	1.7	12
5	Hemoperfusion through polymer-coated adsorbents for metabolic disorders in liver disease. *Die Makromolekulare Chemie*, **1985**, 9, 81-84		1
4	Resin hemoperfusion in hepatic porphyrias. *Artificial Organs*, **1985**, 9, 169-72	2.6	3
3	Homozygous variegate porphyria. *Lancet, The*, **1984**, 1, 851	40	25
2	Porphyrinogens in plasma. *Archives of Dermatology*, **1982**, 118, 624-5		5
1	Porphyrinogens in urine in various types of porphyrias. *Clinical Chemistry and Laboratory Medicine*, **1982**, 20, 113-7	5.9	1